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Developmental Biology
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in
the central nervous system and blocks definitive hematopoiesis
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ABSTRACT The CBFA2 (AMLI) gene encodes a DNA-
binding subunit of the heterodimeric core-binding factor. The
CBFA2 gene is disrupted by the (8;21), (3;21), and (12;21)
chromosomal translocations associated with leukemias and
myelodysplasias in humans. Mice lacking a CBFa2 protein
capable of binding DNA die between embryonic days 11.5 and
12.5 due to hemorrhaging in the central nervous system
(CNS), at the nerve/CNS interfaces of cranial and spinal
nerves, and in somitic/intersomitic regions along the pre-
sumptive spinal cord. Hemorrhaging is preceded by symmet-
ric, bilateral necrosis in these regions. Definitive erythropoi-
esis and myelopoiesis do not occur in Cbfa2-deficient embryos,
and disruption ofone copy ofthe Cbfa2 gene significantly reduces
the number of progenitors for erythroid and myeloid cells.
The core-binding factor (CBF) binds to YGYGGT (Y, pyrim-
idine) sites in many genes expressed in hematopoietic cells,
including genes encoding cytokines, cell surface differentia-
tion markers, and myeloid specific proteins (1). CBF consists
of two unrelated subunits, a DNA-binding a subunit that
contacts DNA directly, and a ,3 subunit that forms a complex
with the a subunit but does not itself bind DNA (2-4). The
mammalian CBFa subunits are encoded by three distinct
genes (CBFA1, CBFA2, and CBFA3), and one gene, CBFB,
encodes the 13 subunit (2-8).
Two of the four genes encoding subunits of CBF are among
the most frequently disrupted genes in human leukemias. The
CBFA2 gene is disrupted by chromosomal translocations as-
sociated with de novo acute myeloid leukemia (AML) [t(8;21),
AML M2 subtype] (6, 9-11), therapy-related myeloid leuke-
mias, myelodysplasias, and chronic myelogenous leukemia in
blast crisis [t(3;21)] (12, 13), and with pediatric B-cell acute
lymphoblastic leukemias [t(12;21)] (14, 15). These transloca-
tions create chimeric proteins containing various portions of
the CBFa2 protein that include its DNA-binding domain,
fused to sequences from another protein: ETO (MTG8) in the
case of t(8;21), EAP, MDS1 or EVIl in t(3;21), and TEL in the
t(12;21). The CBFB gene is disrupted by inv(16) and t(16;16)
in AML of the M4Eo subtype. The chimeric proteins that
result from inv(16) and t(16;16) contain the heterodimeriza-
tion domain in CBFj3 fused to the coiled-coil tail region of a
smooth muscle myosin heavy chain (8, 16). Together, trans-
locations and inversions involving the CBFA2 and CBFB genes
are associated with up to 30% of de novo AML cases and 28%
of pediatric acute lymphoblastic leukemia (ALL) (17-20).
The Drosophila melanogaster homologue of the CBFA2
gene, the runt gene, is involved in several developmental
pathways in Drosophila-segmentation, sex determination,
and neurogenesis (21-24). Here we analyze the functions of
CBFA2 in mammalian development by gene disruption in mice.
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement" in
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MATERIALS AND METHODS
Recombination Constructs and Targeting of Embryonic
Stem (ES) Cells. The targeting vector replaces a 3.2-kb region
encompassing the last exon encoding amino acids in the
DNA-binding domain of the CBFa2 protein (exon 4) with the
neo gene driven by the phosphoglycerol kinase promoter
(PGKneo) and linked to PGK poly(A) sequences. A thymidine
kinase gene (tk) under the regulation of the PGK promoter
was incorporated at the 3' end of the targeting vector. The
PGKneo gene was flanked upstream and downstream by 4.1
and 4.3 kb of Cbfa2 homology, respectively. The targeting
vector was linearized with Not I and electroporated into Jl ES
cells. G418r and 1-(2-deoxy, 2-fluoro P3-D-arabinofuranosyl)-
5-isodouracil (Eli Lilly) (FIAU)r ES cell colonies were picked
and expanded as described (25) and screened for homologous
recombination by Southern blotting. Two independent ES cell
clones heterozygous for the Cbfa2 mutation were injected into
blastocysts derived from C57BL/6 and BALB/c mice. Chi-
meric animals were bred against the appropriate background,
and Cbfa2+/- F1 mice (129 X BALB/c or 129 x C57BL/6)
were mated. No phenotypic differences were observed in
progeny mice derived either from independently targeted ES
cell clones or on different genetic backgrounds.
Cbfa2-/- ES cells were selected from Cbfa2+/- JI cells by
growth in G418 (3.2 mg/ml) (26).
Cbfa2 cDNA Analysis. Total RNA was prepared from liver
of embryonic day 12.5 (E12.5) embryos (27) and reverse
transcribed with random hexamers (Invitrogen). Nested PCR
amplifications were performed on the region spanning exons
1-4 using the following primers: 5'-TATCCCCGTAGATGC-
CAG-3' and 5'-GCCGTCCACTGTGATTTTGATGG-3' for
the primary PCR; 5'-TATCCCCGTAGATGCCAG-3' and
5'-GATGGTCAGAGTGAAGCT-3' for the second round of
PCR. Primers for 3-actin (Stratagene) were used as a control.
PCR amplifications (Perkin-Elmer/Cetus) were performed
for 30 cycles (94°C, 2 min; 50°C, 2 min; 72°C, 2 min). The PCR
product was confirmed by Southern blotting.
Histological Analysis of Cbfa2 Mutant Embryos. Embryos
at various stages of gestation were fixed in Bouin's fluid,
processed, and embedded in paraffin. Transverse sections of
entire embryos were cut at 8 Jtm thickness, mounted, and
stained with hematoxylin and eosin. Yolk sacs from E10.5
embryos were teased into 1 ml of phosphate-buffered saline to
liberate the hematopoietic cells, and cytospin preparations
were stained with Wright-Giemsa stain.
Methylcellulose Colony-Forming Assays. Single cell suspen-
sions of yolk sac cells were prepared by digestion in 0.1%
collagenase (Sigma), 20% fetal calf serum (FCS; HyClone) at
37°C for 1 hr. Cells were washed twice with a minimum
essential medium (GIBCO/BRL), 2% FCS, and were plated
Abbreviations: CBF, core-binding factor; CNS, central nervous sys-
tem; ES cell, embryonic stem cell; E, embryonic day; EB, embryoid
body.¶To whom reprint requests should be addressed.
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in a methylcellulose medium (0.8% methylcellulose/30%
FCS/1% bovine serum albumin/2 mM L-glutamine/0.1 mM
2-mercaptoethanol) (Methocult M3230; Stemcell Technolo-
gies, Vancouver) with lx penicillin/streptomycin (GIBCO/
BRL), erythropoietin (2 units/ml) (R&D Systems), and 1.3%
pokeweed mitogen-stimulated spleen cell conditioned medium(Stemcell Technologies).
In Vitro Differentiation of ES Cells. Cbfa2+/+ and Cbfa2-/-
J1 ES cells were differentiated in vitro according to the
protocols of Keller et al. (28), with the following modifications:
Primary differentiation to embryoid bodies (EBs) was in
Iscove's modified Dulbecco's medium (IMDM; GIBCO/
BRL)/15% FCS/0.8% methylcellulose (Methocult M3100;
Stemcell Technologies)/2 mM glutamine/450/uM monothio-
glycerol (Sigma)/1 x OPI medium supplement (oxalacetic
acid/sodium pyruvate/bovine insulin; Sigma). Secondary he-
matopoietic colonies were grown in IMDM/10% FCS/0.8%
methylcellulose/2 mM glutamine/100 ng of recombinant mu-
rine stem cell factor per ml (SCF; R&D Systems)/2 units of
human recombinant erythropoietin per ml (R&D Systems)/10 ng
A
Cbfa2 locus
targeting vector
mutant locus
B
of recombinant murine interleukin 3 per ml (Stemcell Technol-
ogies)/10 ng of recombinant murine granulocyte-macrophage
colony-stimulating factor per ml (Stemcell Technologies).
RESULTS
Mutation ofthe Cbfa2 Gene Results in Embryonic Lethality.
The DNA-binding domain of CBFa2 is contained within a
128-amino acid region (aa 51-178) called the Runt domain (2,
29, 30). We replaced the last exon (exon 4) encoding amino
acids in the Runt domain of CBFa2 (aa 143-178; ref. 7) with
the neomycin-resistance gene (Fig. 1). Since a C-terminal
truncation of CBFa2 to aa 170 was sufficient to disrupt
DNA-binding and heterodimerization with CBFj3 (31), loss of
exon 4-encoded sequences should destroy the ability ofCBFa2
to bind DNA and heterodimerize with the CBF,3 subunit.
Chimeric mice generated from two independently targeted ES
cell clones were bred to C57BL/6 or BALB/c mice and
progeny heterozygous for the Cbfa2 mutation were interbred.
Cbfa2-/- embryos died between gestational days E11.5 and
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FIG. 1. Disruption of the Cbfa2 gene by homologous recombination. (A) Gene-targeting strategy used to delete exon 4 (E4) of the Cbfa2 gene.Probe A, from outside the recombination locus, was used to screen for homologous recombination events. Probe B, from the neomycin resistance
gene, was used to check single integration events. Probe C is derived from the region deleted in the recombination vector. B, BamHI; S, Ssp I. (B)Southern blot analysis of genomic DNA from eight selected ES cell clones. Probe A hybridizes to a 7.5- and a 5.0-kb BamHI genomic fragmentderived from the wild-type and the targeted Cbfa2 alleles, respectively. Probe B hybridizes to a 10.0-kb Ssp I genomic fragment derived from the
targeted locus. (C) Southern analysis ofDNA from E11.5 Cbfa2+/+, Cbfa2+/-, and Cbfa2-/- embryos. Probe C hybridizes to a 7.5-kb BamHI bandfrom the wild-type allele and probe B hybridizes to a 5.2-kb band from the targeted allele. (D) Analysis of Cbfa2 mRNA expression in F2 embryosby reverse transcription PCR. M, markers. Arrowheads indicate expected size of the PCR products.
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E12.5 and exhibited extensive hemorrhages (Fig. 2 A and B;
Table 1). Hemorrhaging in Cbfa2-/- embryos occurred as
early as E10.5 (14%), by E11.5 most (73%) of the Cbfa2-/-
embryos had hemorrhaged, and by E12.5 all live Cbfa2-/-
embryos had hemorrhaged. Aside from hemorrhaging,
Cbfa2-/- embryos and yolk sacs appeared to be developmen-
tally normal by gross morphologic analysis (Fig. 2A).
We recognized three different types of primary hemorrhagic
events: (i) The most extensive bleeds were those involving the
central nervous system (CNS) and were specifically located in
the isthmus, ventral metencephalon, and spinal cord (Fig. 2
B-D). The CNS acquires its vascular network from capillaries
that perforate the neural tissue from the surrounding menin-
geal compartment (32). Early CNS hemorrhages were linear
and paralleled the location and distribution of these CNS
perforating capillaries (Fig. 2D). These bleeds often ruptured
through the ependymal epithelium, causing secondary and
possibly terminal intraventricular hemorrhages (Fig. 2 B-D).
We also identified two bilateral, symmetrical foci of cellular
necrosis within the ventral metencephalon (Fig. 2C). This
necrosis appeared to involve the endothelial cells of growing
Table 1. Genotype of offspring derived from intercross of
Cbfa2+/- parents
Total Genotype
Stage (litters) +/+ +/- -/- Live -/-
Postnatal 122 (24) 44 78 0 0
E14.5 6(1) 0 5 1 0
E12.5 18(3) 3 12 3 2
E11.5 148 (16) 22 86 40 35
E10.5 78(11) 23 41 14 14
Genotype analysis was performed by Southern blot analysis ofDNA
isolated from tail snips at the postnatal stage and from yolk sacs or
embryos at prenatal stage. Surviving embryos were defined as those
with beating hearts at the time of dissection.
CNS capillaries and not nerve tissue (not shown). (ii) Focal
petechial (often bilateral and symmetrical) hemorrhages were
seen in peripheral nerves and intersegmental regions. They
were especially prominent at the nerve roots of the VII-VIII
cranial nerve complex and at some spinal nerves (Fig. 2B). (iii)
Mesodermal petechial hemorrhages were detected in a small
...
+1+
Z
FIG. 2. Composite figure showing gross and microscopic views of the observed pathologic lesions. (A) Gross appearance of two El11.5 littermates
showing a Cbfa2-/- embryo (Left) with a ventral metencephalic hemorrhagic area (arrowhead) roughly located at the level of the VII-VIII cranial
nerve complex and close to the otic placode (arrowhead). (Right) Unaffected Cbfa2+/- embryo. (B) Gross appearance of an E11.5 Cbfa2-/- embryo
with several hemorrhagic lesions, including intraventricular (lateral, 3rd, infundibulum, aqueduct, and 4th ventricle), and segmental bleeds in various
regions: at the VII-VIII cranial nerve complex (1), cervical (2), thoracic (3), and caudal (4) regions. (C) Cross section of the CNS isthmus of an
El 1.0 Cbfa2-/- embryo showing extensive CNS hemorrhages (B) and bilateral symmetrical areas of vascular necrosis (N). There is also blood in
the ventricle (*). (D) Detail of the same isthmus from a margin of the hemorrhage in C, showing several separate lineal and vertical hemorrhages
(arrowheads), paralleling the location and distribution of the CNS perforating vessels. Also shown is intraventricular blood (*). (E) Detail of the
CNS/nerve interface of the VII-VIII cranial nerve complex of an E10.5 Cbfa2-/- embryo showing extensive necrosis (N) involving neural crest
and endothelial cells. Note a few cells in mitosis (arrowheads), indicating the great cellular activity of these CNS/nerve interfaces. This corresponds
to the area of bleeding shown at E11.5 (A, arrowhead; B, 1). Also shown is the edge of the otic (0) placode. (F) Detail of the somitic (S) intersomitic
necrosis (N) around and probably involving segmental vessels (c) in an E10.5 Cbfa2-/- embryo. (See B, areas 2-4.) (G and H) Details of cytospin
preparations from E10.5 yolk sacs showing blood precursor cells and nucleated primitive erythrocytes from Cbfa2+/+ and Cbfa2-/- embryos. (I
andJ) Detail of liver sections showing many blood precursor cells in the liver sinusoids (S) of an E11.0 Cbfa2+/+ embryo and their absence in the
liver sinusoids (S) of the Cbfa2-/- embryo, which essentially contains only circulating nucleated primitive erythrocytes. Arrowheads in I point to
examples of nucleated primitive erythroid cells; remaining cells in the sinusoids of Cbfa2+/+ livers are less differentiated hematopoietic cells.
,
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number of embryos. Pericardiac and peritoneal hemorrhages,
for which we could not identify a source, were also found in
some embryos. These latter bleeds may represent late events
resulting from terminal embryonic deterioration and/or han-
dling at the time of dissection.
To gain insight into the cause of bleeding, and to identify
events that precede hemorrhaging, we analyzed younger
Cbfa2-/- embryos. We observed foci of cellular necrosis,
often bilateral and symmetrical, at the nerve/CNS interfaces
of cranial and spinal nerves of E10.5 embryos (Fig. 2E) and
somitic/intersomitic necrosis in the lower thoracic and lumbar
regions (Fig. 2F). Their locations paralleled the segmental
bleeds observed in E11.5-E12.5 embryos (Fig. 2B). The
necrosis in these regions appears to involve neural crest cells
and endothelial cells. Substantial areas of necrosis were found
in only three regions (CNS capillaries, nerve/CNS interfaces,
and somitic/intersomitic regions). However, scattered micro-
scopic foci of perineural necrosis were detected throughout the
mesoderm and retroperitoneal regions of E10.5 embryos that
seemed to be more common in Cbfa2-/- embryos than in
Cbfa2+/+ littermates.
Mutation of the Cbfa2 Gene Blocks Definitive Erythropoi-
esis and Myelopoiesis. Mutation of the Cbfa2 gene caused no
gross differences in either the number or morphology of
primitive erythrocytes in E10.5 Cbfa2-/- yolk sacs (Fig. 2 G
and H), but fetal liver hematopoiesis was impaired. Liver
sinusoids from E11.0 +/+ embryos contained primitive nu-
cleated erythrocytes plus numerous, less differentiated cells
(Fig. 2I). Immature granulocytes and monocytes/macro-
phages were also found in liver smears from E12.5+/' embryos
stained by Wright-Giemsa or for myeloperoxidase activity
(not shown). In contrast, only primitive nucleated erythroid
cells could be detected either in liver sections from E11.0
Cbfa2-/- embryos (Fig. 2J) or in liver smears from E12.5
embryos (not shown).
Mutation of the Cbfa2 gene could affect either homing of
hematopoietic progenitor cells to the liver or the ability of the
fetal liver microenvironment to support hematopoiesis. To
assess the differentiation capacity of progenitor cells isolated
from yolk sacs of Cbfa2+/+, Cbfa2+/-, and Cbfa2-/- embryos,
we performed in vitro methylcellulose colony-forming assays
(Table 2) (33). Definitive erythroid, myeloid, and mixed
erythroid/myeloid colonies differentiated from Cbfa2+/+ and
Cbfa2+/- yolk sac cells. Significantly fewer colonies differen-
tiated from yolk sac cells isolated from Cbfa2+/- embryos
compared to those from Cbfa2+/+ embryos (Table 2). Essen-
tially no erythroid or myeloid colonies appeared when yolk sac
cells from Cbfa2-/- embryos were cultured in the same manner.
In vitro differentiation of Cbfa2-/- ES cells (28) also
indicated that this gene plays a role in either the commitment
or the differentiation of definitive erythroid and myeloid
progenitor cells. In primary differentiation cultures, both
Cbfa2+/+ and Cbfa2-/- ES cells formed hemaglobinized EBs.
Primitive erythroid cells were seen in cytospin preparations of
the disaggregated cells from both Cbfa2+/+ and Cbfa2-/- EBs
(not shown). However, after disaggregation of the EBs and
secondary culture of the cells in the presence of hematopoietic
growth factors, only cells derived from Cbfa2+/+ EBs, and not
those from Cbfa2-/- EBs, were able to form definitive ery-
throid and myeloid colonies (Table 2).
DISCUSSION
Lack of a CBFa2 protein capable of binding specific DNA
target sequences and dimerizing with the CBFP subunit leads
to extensive hemorrhaging and ultimately embryonic death.
The hemorrhaging occurred at specific sites in the embryo-at
nerve/CNS interfaces, in the CNS vasculature in the meten-
cephalon, and in somitic/intersomic zones. This localized
hemorrhaging differs from the more generalized impairment
of vasculogenesis and hemorrhage seen upon disruption of the
tek Flk-1, Flt-1, Tie-1, Tie-2, and Gap genes (34-38). Hemor-
rhaging in E11.5-E12.5 Cbfa2-/- embryos was preceded by
cellular necrosis at E10.5 in these same regions. The symmetrical,
bilateral nature of the necroses indicates that there is a specific
developmental defect caused by mutation of the Cbfa2 gene.
The Cbfa2 gene is widely expressed in the mouse embryo
(39). Expression starts at E9.2, and by E10.5 Cbfa2 transcripts
are found in the neural tube, sensory ganglia (notably cranial
nerves V, VII-VIII, and IX and the dorsal root ganglia of
spinal nerves), specialized sensory epithelial structures, chon-
drogenic centers of both neural crest and mesodermal origin,
and the genital system (39). Necrosis and hemorrhaging in the
E10.5-12.5 Cbfa2-/- embryos is found in a subset of those
areas where the gene is normally expressed. Since the nerve/
CNS interfaces and CNS capillaries undergo considerable
cellular growth and migration at this stage of embryonic
development (32, 40-42), this may render them particularly
susceptible to damage. An alternative explanation for the
limited distribution of the necrosis and hemorrhaging relative
to Cbfa2 expression is that the first lesions that develop cause
embryonic death. Additional lesions might have appeared at
later stages of development had the embryos survived longer.
We note that two places where focal necrosis was observed, the
VII-VIII cranial nerve complex and the dorsal root ganglia of
spinal nerves, correspond to areas where substantial expres-
sion of Cbfa2 was seen in E10.5-E12.5 embryos (39).
We believe that cellular necrosis, and not lack of circulating
platelets, is the cause of hemorrhaging for two reasons: First,
the necrosis seen at E10.5 precedes the onset of definitive liver
hematopoiesis (43) and expression of prothrombin (44). Sec-
ond, other mutations that selectively disrupt definitive eryth-
Table 2. Colonies arising from yolk sac progenitors and in vitro differentiation of ES cells
E10.5 E11.5 ES cells
Total no. of Colony no. per yolk sac* Total no. of Colony no. per yolk sac*yolk sacs yolk sacs Primary Secondary
Genotype analyzed E M Mix analyzed E M Mix EBst colony no.t
+/+ 11 221 (61) 224 (64) 54 (24) 6 139 (54) 196 (54) 37 (20) 135 (51) 20 (2)
+/- 19 166 (92) 135 (45) 24 (14) 25 55 (22) 108 (47) 13 (10) ND ND
-/- 5 0 0 1 13 0 0 0 94 (19) 0
*Colonies (>30 cells in size) were scored on day 7 of incubation. E, erythroid colonies; M, myeloid colonies; Mix, erythroid-myeloid mixed colonies.
Average number of colonies per yolk sac is indicated, followed by standard deviation in parentheses. The difference between the numbers of
colonies from Cbfa2+/- and Cbfa2+/+ yolk sacs is significant at P < 0.01, except for the numbers of erythroid colonies from E10.5 yolk sacs, which
is significant at P < 0.1.
tPrimary EBs per 1000 ES cells plated were counted after 6 days of differentiation. Numbers represent means of three plates, each obtained in
two independent experiments. ND, not determined.
tEBs were collected and disaggregated after 6 days of primary differentiation. Numbers of myeloid, erythroid, and mixed colonies per 105 cells
plated were counted after 7 days of secondary differentiation. Numbers represent means of three plates, each obtained in two independent
experiments.
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ropoiesis and myelopoiesis, including mutations in c-myb, and
the genes encoding the c-kit receptor (W) and its ligand (SI),
do not cause hemorrhaging in the CNS (45, 46). Likewise, mice
homozygous for disruption of the NF-E2 gene, which selec-
tively blocks platelet formation, are born alive with birth-
induced abdominal hemorrhages, and a small percentage of
the mice survive into adulthood (47).
Homozygous disruption of the Cbfa2 gene completely
blocks definitive erythropoiesis, myelopoiesis, and lymphopoi-
esis (this paper and ref. 48), suggesting a defect in an early
progenitor cell for all these lineages. Primitive erythropoiesis
is largely intact, although we do discern subtle differences in
the morphology and staining intensity of primitive erythroid
cells from Cbfa2-/- embryos relative to Cbfa2+/+ embryos,
which could indicate a minor impairment in the development
of this lineage. We also find that disruption of one copy of the
Cbfa2 gene decreases the number of erythroid and myeloid
colonies that can be differentiated in vitro. This could result
either from the presence of smaller numbers of progenitor cells
or from an impairment in their capacity to differentiate. The
targeted disruption has either decreased the levels of func-
tional CBFa2 protein or caused a truncated protein to be
produced that functions as a transdominant inhibitor of he-
matopoiesis. Assuming the disruption is a loss-of-function
mutation, we predict that hemizygosity of the CBFA2 gene may
contribute to leukemogenesis in humans. Translocations in the
CBFA2 gene could block differentiation by two mecha-
nisms-by creating chimeric proteins with altered properties
and by decreasing the level of functional CBFa2 protein in the
leukemic cells.
Cbfa2, like its Drosophila homologue runt, appears to be
involved in .multiple developmental pathways. The Drosophila
runt gene plays a vital role in neurogenesis and, like Cbfa2, is
expressed in the CNS (23). However, some mutant alleles of
the runt gene cause defects at very early stages of Drosophila
development, segmentation and sex determination (21, 22, 24),
whereas Cbfa2 appears to play no role in these processes.
Although participation in multiple developmental pathways is an
evolutionarily conserved property of these genes, the particular
pathways in which they function have apparently diverged.
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